About the Real-World Evidence Steering Committee

The Real-World Evidence (RWE) Steering Committee provides strategic advice and support on cutting-edge topics related to the use and/or development of real-world data (RWD) and RWE for regulatory studies. Responsibilities include providing strategic advice and identifying potential synergies between the FDA Foundation and other data/technology, government, academic, and health sector organizations engaged in the use and/or development of RWD and RWE.

The RWE Steering Committee strives for representation from leaders and experts across the health and healthcare ecosystem, including patient groups, health insurance, health care delivery, life sciences industries, and research institutes.

Real-World Evidence Steering Committee Members

Aaron Mendelsohn, PhD, MPH  (Non-voting)
Principal Research Scientist 
Harvard Pilgrim Health Care Institute

Vinit Nair, BPharm, MS, RPh
Chief Strategy Officer 

Christian Nguyen, PharmD, MBA, MS 
Senior Vice President of Value Evidence Outcomes 
Eli Lilly and Company

Sara Tartof, PhD, MPH 
Research Scientist, Epidemiologic Research 
Kaiser Permanente Southern California

FDA Representative (Non-voting)

Peter Marks, MD, PhD 
Director of the Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration